TECNIS PureSee Just Got FDA Approved: Here's What It Means for My Patients

On March 12, 2026, the FDA approved the TECNIS PureSee intraocular lens (IOL) for use in the United States. This marks another advancement in lens technology for patients undergoing cataract surgery or refractive lens exchange.

While new intraocular lenses are introduced periodically, not every approval represents a meaningful change for patients. The TECNIS PureSee IOL is noteworthy because it expands the range of premium lens options available. This gives surgeons another way to personalize vision correction based on a patient's individual needs, lifestyle, and visual goals.

Understanding what the TECNIS PureSee approval means and how it fits into today's lens technologies can help patients make more informed decisions when considering lens replacement surgery.

The TECNIS PureSee IOL is an extended depth of focus (EDOF) intraocular lens designed for patients undergoing cataract surgery or refractive lens exchange. Like other intraocular lenses, it replaces the eye's natural lens after it has been removed.

Unlike traditional monofocal lenses, which provide clear vision at a single focal distance, extended depth of focus lenses are designed to create a broader, more continuous range of vision. This can improve distance and intermediate vision, while also providing functional near vision for many everyday activities.

The goal is to reduce dependence on glasses without sacrificing overall visual quality. Rather than replacing existing lens technologies, the PureSee lens adds another option to the growing family of premium intraocular lenses available today.

Before a new intraocular lens becomes available in the United States, it must undergo extensive clinical testing to evaluate its safety and effectiveness. FDA approval indicates that the device has met established standards based on data collected during clinical studies.

For patients considering cataract surgery or refractive lens exchange, this approval means another thoroughly evaluated option is now available.

One finding highlighted during the FDA approval process was that, according to clinical data reported by the manufacturer, 97% of implanted patients experienced no "very bothersome visual disturbances."

While every patient's experience is different and no intraocular lens is perfect for everyone, these results suggest the TECNIS PureSee IOL may offer a favorable balance between an extended range of vision and overall visual quality.

It's important to remember that FDA approval does not mean one lens is automatically better than every other option. Instead, it gives surgeons another technology that can be matched to the right patient under the right circumstances.

Modern cataract surgery and refractive lens exchange are no longer simply about replacing the eye's natural lens. Today's procedures also provide an opportunity to improve vision by selecting an intraocular lens that aligns with a patient's lifestyle and visual priorities.

Monofocal intraocular lenses provide excellent vision at one primary distance, most commonly for distance vision. Many patients still require reading glasses for near tasks, but monofocal lenses continue to offer outstanding clarity and predictability.

Multifocal lenses use multiple focal points to improve vision at near, intermediate, and distance ranges. They can significantly reduce dependence on glasses, although some patients may experience visual disturbances such as halos or glare, particularly at night.

Extended depth of focus lenses are designed differently. Rather than creating several distinct focal points, they provide a smoother, continuous range of focus. This approach aims to deliver excellent distance and intermediate vision while maintaining good visual quality.

The TECNIS PureSee IOL joins this category of premium lenses, giving surgeons another option for patients seeking greater visual freedom while preserving contrast sensitivity, an important aspect of visual performance that helps people distinguish objects in varying lighting conditions.

Every premium intraocular lens is designed with a slightly different philosophy, balancing the range of vision with visual quality.

One of the goals of the TECNIS PureSee IOL is to provide an extended range of vision while minimizing visual compromises that some patients associate with earlier premium lens technologies. Maintaining strong contrast sensitivity is an important part of that objective, as it contributes to clearer vision in real-world environments with varying light levels.

For many patients, this means the possibility of improved intermediate visual acuity for activities such as working on a computer, cooking, shopping, or viewing a vehicle dashboard. Functional near vision may also be possible for many everyday tasks, although some patients may still require glasses for very small print or prolonged reading.

Like all premium intraocular lenses, the TECNIS PureSee is intended to improve vision, but the results ultimately depend on factors such as eye health, pre-existing eye conditions, and individual healing.

The TECNIS PureSee IOL may be appropriate for a variety of patients who are seeking greater independence from glasses after lens replacement surgery.

Patients who may benefit include:

• Individuals undergoing cataract surgery who want an extended range of vision.

• Patients considering refractive lens exchange to reduce dependence on glasses or contact lenses.

• Adults with presbyopia who would like greater visual freedom for everyday activities.

• Patients who prioritize strong intermediate vision for work, hobbies, and daily life.

• Individuals looking for a balance between visual quality and reduced visual disturbances.

The best candidates are determined through a comprehensive eye examination that considers overall eye health, corneal measurements, lifestyle, and visual expectations.

The FDA approval of the TECNIS PureSee reflects a broader trend in eye care. Rather than relying on a limited number of lens designs, surgeons now have access to an expanding selection of technologies that can be matched to each patient's unique needs.

Not every patient has the same priorities. Some value the widest possible range of vision. Others place greater importance on nighttime driving, contrast sensitivity, or minimizing dependence on glasses for specific activities. Having multiple premium IOL options allows treatment decisions to become increasingly personalized.

As lens technology continues to evolve, the goal is not to identify one universally "best" intraocular lens. Instead, the objective is to select the lens that provides the optimal visual outcomes for each individual patient.

Although the approval of the TECNIS PureSee is an exciting development, choosing an intraocular lens remains one of the most important decisions in cataract surgery or refractive lens exchange. No single lens is ideal for everyone. Factors such as eye health, previous eye surgery, lifestyle, occupation, and long-term vision goals all influence which technology is most appropriate.

Patients seeking greater independence from glasses while maintaining strong visual quality may be good candidates for the TECNIS PureSee IOL. However, patients who want the strongest possible near vision without glasses, or those with certain eye conditions that could affect the performance of premium intraocular lenses, may be better served by a different lens option.

A detailed preoperative evaluation allows an eye surgeon to recommend the lens that best aligns with a patient's needs and expectations.